Inflammatory Disorders

Catalyst's program in this area focuses on the cardiac inflammation associated with acute cardiovascular disorders.

The inflammation program is focused on a key activation component of inflammation, the complement cascade.  A cascade of multiple inflammatory mediators working in concert characterizes inflammation in cardiovascular and other diseases, such as autoimmune disorders.  Catalyst is targeting acute cardiac disorders, including myocardial infarction (MI) and inflammation associated with several other diseases.  The Company has demonstrated the ability of its lead anti-complement Alterase™ therapeutics to saturate several complement targets at far lower doses and with significantly greater effect than relevant benchmark antibodies.

The anti-complement program is in preclinical animal model efficacy studies.